Searchable abstracts of presentations at key conferences in endocrinology

ea0050p383 | Thyroid | SFEBES2017

Novel driver mutations in thyroid cancer recurrence

Nieto Hannah , Fletcher Alice , Thompson Rebecca , Baker Kate , Alshahrani Mohammed , de Menezes Albert Nobre , Read Martin , Boelaert Kristien , Smith Vicki , Cazier Jean-Baptiste , Mehanna Hisham , McCabe Chris

Worldwide, ˜300,000 new cases of differentiated thyroid cancer are reported per annum and thyroid cancer now represents the most rapidly increasing cancer in the US and in the UK. In general terms, outcome is good (10-year survival >90%). However, up to 25% of patients develop local or regional recurrences, and have a significantly reduced life expectancy. We hypothesise those thyroid tumours which subsequently recur display a distinct pattern of driver ...

ea0050oc3.6 | Obesity, Diabetes Thyroid | SFEBES2017

Identification of novel sodium iodide symporter interactors which modulate iodide uptake

Fletcher Alice , Poole Vikki , Modasia Bhavika , Imruetaicharoenchoke Waraporn , Thompson Rebecca , Sharma Neil , Nieto Hannah , Baker Katie , Alshahrani Mohammed , Read Martin , Turnell Andrew , Boelaert Kristien , Smith Vicki , McCabe Christopher

By exploiting the canonical function of the sodium iodide symporter (NIS), ablative radioiodide therapy is an effective treatment for thyroid cancer. However, a subset of patients are unable to accumulate sufficient radioiodide due to decreased expression and/or plasma membrane localisation of NIS. Radioiodide therapy has been proposed as a viable treatment for breast cancer, but is hampered by low levels of NIS membrane localisation. Currently, the regulation of NIS trafficki...

ea0050p383 | Thyroid | SFEBES2017

Novel driver mutations in thyroid cancer recurrence

Nieto Hannah , Fletcher Alice , Thompson Rebecca , Baker Kate , Alshahrani Mohammed , de Menezes Albert Nobre , Read Martin , Boelaert Kristien , Smith Vicki , Cazier Jean-Baptiste , Mehanna Hisham , McCabe Chris

Worldwide, ˜300,000 new cases of differentiated thyroid cancer are reported per annum and thyroid cancer now represents the most rapidly increasing cancer in the US and in the UK. In general terms, outcome is good (10-year survival >90%). However, up to 25% of patients develop local or regional recurrences, and have a significantly reduced life expectancy. We hypothesise those thyroid tumours which subsequently recur display a distinct pattern of driver ...

ea0086oc2.2 | Endocrine Cancer and Late Effects | SFEBES2022

Promotion of thyroid cancer cell migration and invasion by the proto-oncogene PBF is mediated by FGD1 and N-WASP

Manivannan Selvambigai , Alshahrani Mohammed , Thornton Caitlin EM , Raja Saroop , Kocbiyik Merve , Zha Ling , Brookes Katie , Nieto Hannah R , Read Martin L , McCabe Christopher J , Smith Vicki E

Thyroid tumor progression is dependent on cell motility, a highly complex process that involves the co-ordination of cell adhesion, actin dynamics and signal transduction. The proto-oncogene pituitary tumor-transforming gene (PTTG)-binding factor (PBF/PTTG1IP) is a transmembrane glycoprotein that is overexpressed in thyroid cancer and associated with a poorer prognosis. PBF significantly promotes thyroid cancer cell migration and invasion through phosphorylation at PBF-Y174 by...

ea0090p102 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

People With Newly Diagnosed T2DM Showed Significant Improvement in Glycemic Control and Effective Weight Management After Completion of Fitterfly Diabetes Digital Therapeutics Program

Lathia Tejal , Verma Ritika , Khader Mohammed Abdul , Selvan Chitra , C S Dwarakanath , Aggarwal Ajay , Ghanekar Gayatri , Bansal Beena , Goyal Ramesh , Joshi Shilpa , Singal Arbinder

Background and aim: Early glycemic control and weight reduction in diabetes has been associated with prevention of progression of β-cell dysfunction and reduction in diabetes-related complications. Digital therapeutics (DTx) platforms can provide evidence-based therapeutic interventions to improve glycemic control using sustainable behavior change. This study aims at assessing the real-world effectiveness of the Fitterfly Diabetes program in improving glycemic control and...

ea0090ep422 | Diabetes, Obesity, Metabolism and Nutrition | ECE2023

CoMICs (Concise Medical Information Cines) videos on diabetes mellitus and polycystic ovary syndrome have better quality, content, and reliability compared to videos from other sources

Shabbir Dania , Baig Shams Ali , Rahman Fazna , Batool Syeda Sabbah , Kowsik Mukunth , Banerjee Josh , Kumar Kushi , Saiyed Mohammed Faraaz , Venkatesh Vardhan , Iyer Pranav Viswanath , Kempegowda Punith

Introduction: It is important to ensure the information shared on social media is up to date to current clinical practice, reliable and appropriate to the target audience. YouTube is the most popular social media platform for video-based medical information worldwide. You and Your Hormones is a UK-based website endorsed by Society for Endocrinology hosting videos on various medical conditions aimed at the public. CoMICs (Concise Medical Information Cines) are short videos prov...

ea0065oc4.1 | Thyroid | SFEBES2019

A high-throughput yellow fluorescent protein (YFP) cell-based screen identifies autophagy modulators to increase the effectiveness of radioiodine therapy

Read Martin , Baker Katie , Fletcher Alice , Thornton Caitlin , Alshahrani Mohammed , Nieto Hannah , Khan Rashida , Webster Jamie , Haggie Peter , Verkman Alan , Alderwick Luke , Boelaert Kristien , Smith Vicki , McCabe Christopher

New targeted drug strategies are urgently needed to improve radioiodine uptake and efficiently ablate thyroid cancer cells thereby minimising the risk of recurrent disease. High-throughput screening (HTS) offers a promising approach to identify new candidate drugs that will induce sodium iodide symporter (NIS) function to promote iodide uptake. However, significant progress has been limited by a lack of thyroid cell-based assays amenable to HTS. Here, we constructed a thyroid ...

ea0065oc4.6 | Thyroid | SFEBES2019

Driver events in thyroid cancer recurrence

Nieto Hannah , Thornton Caitlin , Fletcher Alice , Menezes Albert Nobre de , Brookes Katie , Alshahrani Mohammed , Read Martin , Boelaert Kristien , Smith Vicki , Cazier Jean-Baptiste , Mehanna Hisham , McCabe Chris

Thyroid cancer is increasing in incidence worldwide. While outcomes are generally good, up to 25% of patients suffer recurrence, and this has a significant impact on their quality of life and life expectancy. We hypothesised that thyroid tumours which recur display a distinct pattern of driver events, present on initial histology. Controlled-access TCGA data on thyroid cancer were downloaded and whole exome sequencing data analysed. An analysis pipeline utilising Platypus, Ann...

ea0065op2.4 | Thyroid | SFEBES2019

The proto-oncogene PBF mediates Src modulation of radioiodine uptake

Alshahrani Mohammed , Fletcher Alice , Thornton Caitlin , Brookes Kate , Nieto Hannah , Thompson Rebecca , Raja Saroop , Read Martin , Boelaert Kristien , McCabe Christopher , Smith Vicki

Successful responses to radioiodine treatment in differentiated thyroid cancer ultimately depend on uptake via the sodium-iodide symporter (NIS). However, many tumors exhibit NIS dysregulation, resulting in a poorer prognosis. Since breast cancer can also overexpress NIS, albeit of limited function, radioiodine treatment may be a promising treatment option. Our previous data show that overexpression of the pituitary tumor-transforming gene-binding factor (PBF) is partially res...

ea0065p393 | Thyroid | SFEBES2019

Investigating the mechanism behind sodium-iodide symporter trafficking by the small GTPase ARF4

Thornton Caitlin EM , Fletcher Alice , Nieto Hannah , Brookes Kate , Alshahrani Mohammed , Read Martin , Boelaert Kristien , Stewart Grant S , Smith Vicki E , McCabe Chris

Dysfunctional regulation of sodium-iodide symporter (NIS) trafficking can result in ineffective radioiodide uptake in patients with differentiated thyroid cancer. Understanding the trafficking pathways of this key protein can be used to optimise radioiodide therapy. Recently, we identified via HiLo microscopy that the protein ADP-ribosylation Factor 4 (ARF4) helps shuttle NIS to the plasma membrane. To understand how ARF4 interacts with NIS mechanistically, we utilised advance...